ID

36604

Description

A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "BIRCH"; ODM derived from: https://clinicaltrials.gov/show/NCT02031458

Link

https://clinicaltrials.gov/show/NCT02031458

Keywords

  1. 5/26/19 5/26/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

May 26, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Non-Small Cell Lung Cancer NCT02031458

Eligibility Non-Small Cell Lung Cancer NCT02031458

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients, >/= 18 years of age
Description

Adult | Age

Data type

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
locally advanced or metastatic (stage iiib, stage iv, or recurrent) non-small cell lung cancer (nsclc)
Description

Non-Small Cell Lung Carcinoma Advanced Locally TNM clinical staging | Non-small cell lung cancer metastatic TNM clinical staging | Non-small cell lung cancer recurrent

Data type

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0205179
UMLS CUI [1,3]
C1517927
UMLS CUI [1,4]
C3258246
UMLS CUI [2,1]
C0278987
UMLS CUI [2,2]
C3258246
UMLS CUI [3]
C0278517
representative formalin-fixed paraffin-embedded (ffpe) tumor specimens
Description

Tumor Formalin-fixed paraffin-embedded tissue specimen

Data type

boolean

Alias
UMLS CUI [1,1]
C0027651
UMLS CUI [1,2]
C2711483
pd-l1-positive tumor status as determined by an ihc assay based on pd-l1 expression on tumor infiltrating immune cells and/or tumor cells performed by a central laboratory
Description

Tumor status PD-L1 Positive Immunohistochemistry | PD-L1 Expression Immune Cell Tumor infiltration

Data type

boolean

Alias
UMLS CUI [1,1]
C0475752
UMLS CUI [1,2]
C4284303
UMLS CUI [1,3]
C0021044
UMLS CUI [2,1]
C4284303
UMLS CUI [2,2]
C4330475
UMLS CUI [2,3]
C4060690
measurable disease, as defined by recist v1.1
Description

Measurable Disease

Data type

boolean

Alias
UMLS CUI [1]
C1513041
eastern cooperative oncology group (ecog) performance status of 0 or 1
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exception are allowed:
Description

Cancer treatment | Chemotherapy | Hormone Therapy

Data type

boolean

Alias
UMLS CUI [1]
C0920425
UMLS CUI [2]
C0392920
UMLS CUI [3]
C0279025
hormone-replacement therapy or oral contraceptives tkis approved for treatment of nslc discontinued > 7 days prior to cycle 1, day 1
Description

Exception Hormone replacement therapy | Exception Oral Contraceptives | Exception Tyrosine kinase inhibitor Treating Non-Small Cell Lung Carcinoma

Data type

boolean

Alias
UMLS CUI [1,1]
C1705847
UMLS CUI [1,2]
C0282402
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0009905
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C1268567
UMLS CUI [3,3]
C1522326
UMLS CUI [3,4]
C0007131
central nervous system (cns) disease, including treated brain metastases.
Description

CNS disorder | Metastatic malignant neoplasm to brain Treated

Data type

boolean

Alias
UMLS CUI [1]
C0007682
UMLS CUI [2,1]
C0220650
UMLS CUI [2,2]
C1522326
malignancies other than nsclc within 5 years prior to randomization, with the exception of those with negligible risk of metastases or death and treated with expected curative outcome
Description

Malignant Neoplasms | Exception Non-Small Cell Lung Carcinoma | Exception Low Risk Neoplasm Metastasis | Exception Low Risk Death | Exception Curative treatment Malignant Neoplasms

Data type

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007131
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C3538919
UMLS CUI [3,3]
C0027627
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C3538919
UMLS CUI [4,3]
C0011065
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C1273390
UMLS CUI [5,3]
C0006826
history of autoimmune disease
Description

Autoimmune Disease

Data type

boolean

Alias
UMLS CUI [1]
C0004364
history of idiopathic pulmonary fibrosis (including pneumonia), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening ct scan. history of radiation pneumonitis in the radiation field (fibrosis) id permitted.
Description

Idiopathic Pulmonary Fibrosis | Pneumonia | Drug-induced pneumonitis | Organized pneumonia | Pneumonitis CT scan | Radiation Pneumonitis Radiation Field allowed

Data type

boolean

Alias
UMLS CUI [1]
C1800706
UMLS CUI [2]
C0032285
UMLS CUI [3]
C1960026
UMLS CUI [4]
C0264383
UMLS CUI [5,1]
C3714636
UMLS CUI [5,2]
C0040405
UMLS CUI [6,1]
C0206063
UMLS CUI [6,2]
C1882536
UMLS CUI [6,3]
C0683607
active hepatitis b or hepatitis c
Description

Hepatitis B | Hepatitis C

Data type

boolean

Alias
UMLS CUI [1]
C0019163
UMLS CUI [2]
C0019196
hiv positive
Description

HIV Seropositivity

Data type

boolean

Alias
UMLS CUI [1]
C0019699
prior treatment with cd137 agonists, anti-ctla4, anti-pd-1, or anti-pd-l1 therapeutic antibody or pathway-targeting agents
Description

Prior Therapy | CD137 agonists | Anti-CTLA-4 Monoclonal Antibody | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | Pathway Targeting Agent

Data type

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2,1]
C0214721
UMLS CUI [2,2]
C0243192
UMLS CUI [3]
C4289973
UMLS CUI [4]
C4289970
UMLS CUI [5]
C4289971
UMLS CUI [6,1]
C0037080
UMLS CUI [6,2]
C1521840
UMLS CUI [6,3]
C1254351

Similar models

Eligibility Non-Small Cell Lung Cancer NCT02031458

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age
Item
adult patients, >/= 18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Non-Small Cell Lung Carcinoma Advanced Locally TNM clinical staging | Non-small cell lung cancer metastatic TNM clinical staging | Non-small cell lung cancer recurrent
Item
locally advanced or metastatic (stage iiib, stage iv, or recurrent) non-small cell lung cancer (nsclc)
boolean
C0007131 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C3258246 (UMLS CUI [1,4])
C0278987 (UMLS CUI [2,1])
C3258246 (UMLS CUI [2,2])
C0278517 (UMLS CUI [3])
Tumor Formalin-fixed paraffin-embedded tissue specimen
Item
representative formalin-fixed paraffin-embedded (ffpe) tumor specimens
boolean
C0027651 (UMLS CUI [1,1])
C2711483 (UMLS CUI [1,2])
Tumor status PD-L1 Positive Immunohistochemistry | PD-L1 Expression Immune Cell Tumor infiltration
Item
pd-l1-positive tumor status as determined by an ihc assay based on pd-l1 expression on tumor infiltrating immune cells and/or tumor cells performed by a central laboratory
boolean
C0475752 (UMLS CUI [1,1])
C4284303 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,3])
C4284303 (UMLS CUI [2,1])
C4330475 (UMLS CUI [2,2])
C4060690 (UMLS CUI [2,3])
Measurable Disease
Item
measurable disease, as defined by recist v1.1
boolean
C1513041 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Cancer treatment | Chemotherapy | Hormone Therapy
Item
any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exception are allowed:
boolean
C0920425 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C0279025 (UMLS CUI [3])
Exception Hormone replacement therapy | Exception Oral Contraceptives | Exception Tyrosine kinase inhibitor Treating Non-Small Cell Lung Carcinoma
Item
hormone-replacement therapy or oral contraceptives tkis approved for treatment of nslc discontinued > 7 days prior to cycle 1, day 1
boolean
C1705847 (UMLS CUI [1,1])
C0282402 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0009905 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C1268567 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C0007131 (UMLS CUI [3,4])
CNS disorder | Metastatic malignant neoplasm to brain Treated
Item
central nervous system (cns) disease, including treated brain metastases.
boolean
C0007682 (UMLS CUI [1])
C0220650 (UMLS CUI [2,1])
C1522326 (UMLS CUI [2,2])
Malignant Neoplasms | Exception Non-Small Cell Lung Carcinoma | Exception Low Risk Neoplasm Metastasis | Exception Low Risk Death | Exception Curative treatment Malignant Neoplasms
Item
malignancies other than nsclc within 5 years prior to randomization, with the exception of those with negligible risk of metastases or death and treated with expected curative outcome
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007131 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C3538919 (UMLS CUI [3,2])
C0027627 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C3538919 (UMLS CUI [4,2])
C0011065 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C1273390 (UMLS CUI [5,2])
C0006826 (UMLS CUI [5,3])
Autoimmune Disease
Item
history of autoimmune disease
boolean
C0004364 (UMLS CUI [1])
Idiopathic Pulmonary Fibrosis | Pneumonia | Drug-induced pneumonitis | Organized pneumonia | Pneumonitis CT scan | Radiation Pneumonitis Radiation Field allowed
Item
history of idiopathic pulmonary fibrosis (including pneumonia), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening ct scan. history of radiation pneumonitis in the radiation field (fibrosis) id permitted.
boolean
C1800706 (UMLS CUI [1])
C0032285 (UMLS CUI [2])
C1960026 (UMLS CUI [3])
C0264383 (UMLS CUI [4])
C3714636 (UMLS CUI [5,1])
C0040405 (UMLS CUI [5,2])
C0206063 (UMLS CUI [6,1])
C1882536 (UMLS CUI [6,2])
C0683607 (UMLS CUI [6,3])
Hepatitis B | Hepatitis C
Item
active hepatitis b or hepatitis c
boolean
C0019163 (UMLS CUI [1])
C0019196 (UMLS CUI [2])
HIV Seropositivity
Item
hiv positive
boolean
C0019699 (UMLS CUI [1])
Prior Therapy | CD137 agonists | Anti-CTLA-4 Monoclonal Antibody | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | Pathway Targeting Agent
Item
prior treatment with cd137 agonists, anti-ctla4, anti-pd-1, or anti-pd-l1 therapeutic antibody or pathway-targeting agents
boolean
C1514463 (UMLS CUI [1])
C0214721 (UMLS CUI [2,1])
C0243192 (UMLS CUI [2,2])
C4289973 (UMLS CUI [3])
C4289970 (UMLS CUI [4])
C4289971 (UMLS CUI [5])
C0037080 (UMLS CUI [6,1])
C1521840 (UMLS CUI [6,2])
C1254351 (UMLS CUI [6,3])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial